Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved symbols : Lly save search
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’sAgency to convene an advisory committee to consider the drug
Published: 2024-03-08 (Crawled : 15:30) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -2.29%
fda drug approval treatment
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
Published: 2023-12-01 (Crawled : 23:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
| Email alert
Add to watchlist
jaypirca fda approved treatment leukemia
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Published: 2023-11-17 (Crawled : 18:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -1.71%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
ebglyss dermatitis approval
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
Published: 2023-11-08 (Crawled : 21:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.29%
H: 3.0%
C: 1.89%
fda obesity treatment medical tirzepatide
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-10-26 (Crawled : 23:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.09%
H: 0.0%
C: 0.0%
fda active treatment
U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors
Published: 2023-10-09 (Crawled : 18:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.21%
H: 2.8%
C: 1.37%
foundationone drug diagnostic food tumors companion
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
Published: 2023-09-22 (Crawled : 15:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.93%
H: 1.22%
C: 0.32%
jardiance fda disease kidney treatment
Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
Published: 2023-08-22 (Crawled : 12:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.3%
H: 1.19%
C: 0.75%
retevmo approved cancer thyroid
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
Published: 2023-07-25 (Crawled : 13:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.34%
H: 0.69%
C: -0.05%
jardiance disease kidney approved treatment
US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older
Published: 2023-06-21 (Crawled : 22:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.56%
H: 0.18%
C: -0.33%
jardiance fda children treatment diabetes
Global Axial Spondyloarthritis Treatment Market to 2027: Increase in the Number of Approved Biosimilars Fuels the Sector
Published: 2023-06-16 (Crawled : 02:00) - prnewswire.com
UCBJY | $64.07 -4.38% 72K
|
Manufacturing
|
| O: 1.21%
H: 0.0%
C: -0.2%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.28%
H: 1.25%
C: 0.5%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.46%
H: 0.31%
C: -0.15%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.26%
C: -1.77%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.32%
H: 2.1%
C: 1.97%
approved treatment global market
U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib)
Published: 2023-06-09 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: -0.73%
foundationone drug diagnostic food companion
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
Published: 2023-05-10 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.54%
H: 2.89%
C: 2.31%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.75%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.29%
H: 0.07%
C: -1.6%
tyvyt china therapy
Non-steroidal Anti-inflammatory Drugs Market Report 2023: Quick Authority Approvals by Governments and Increase in Government Initiatives Presents Opportunities
Published: 2023-04-27 (Crawled : 00:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.21%
H: 0.12%
C: -2.76%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.41%
H: 0.79%
C: 0.79%
RBGLY | $10.29 -2.05% 1.4M
|
Manufacturing
|
| O: 2.25%
H: 0.31%
C: 0.06%
PRGO | $29.94 -0.33% 0.0% 970K
|
Health Technology
|
| O: 0.11%
H: 1.61%
C: 1.42%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.12%
H: 0.58%
C: 0.55%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.25%
H: 0.97%
C: 0.31%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.96%
H: 1.59%
C: -0.54%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -2.09%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.03%
H: 1.02%
C: 0.28%
report market
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Published: 2023-04-20 (Crawled : 12:20) - biospace.com/
BWV | $0.1802 5.44% 530K
|
|
| O: 1.51%
H: 2.73%
C: -2.73%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.25%
H: 1.26%
C: 0.92%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 2.91%
H: 16.04%
C: 13.21%
entadfi water acquisition blue
Global Biosimilars Business and Investment Opportunities 2023: Attractive Approval Numbers Present Fertile Ground for New Entrants
Published: 2023-04-18 (Crawled : 18:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.17%
H: 0.34%
C: -0.83%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.45%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 0.05%
H: 0.77%
C: 0.5%
business approval global
U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor
Published: 2023-01-27 (Crawled : 20:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.55%
H: 0.57%
C: -1.16%
fda
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
Published: 2023-01-19 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.16%
H: 0.6%
C: -0.27%
drug approval response food
China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List
Published: 2023-01-19 (Crawled : 04:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.26%
H: 1.19%
C: 1.19%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.1%
H: 0.97%
C: -0.37%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
drug approved
Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy
Published: 2022-12-19 (Crawled : 12:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.57%
H: 0.53%
C: -0.01%
EGRX | $4.505 2.62% 2.55% 140K
|
Health Technology
|
| O: 3.31%
H: 0.46%
C: -0.89%
pemfexy fda pharmaceuticals approval
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.